Rumours of
Novartis taking over small Biotech have stirred the biotech market.
Morgan Stanley has upgraded Novartis' stock rating to Equalweight due to its growth profile leading to an upturn in Novartis shares. Further confirming this trend, Bernstein has maintained a 'Buy' rating on Novartis with a CHF108 Price Target. Additional acquisitions are on the horizon as Novartis eyes
Avidity Biosciences. Strong performance reports and raised Q2 earnings have rendered Novartis a worthy long-term value stock. Its robust portfolio, particularly its Oncology brands, drives growth, offsetting challenges from U.S. competition and China slowdown. Despite this, rumours of generic competition have raised concerns and led to a drop in stock price. Novartis recently acquired
Regulus Therapeutics for $1.7 billion, boosting its biotech shares significantly. The company trades strongly, with indicators suggesting Novartis stocks are undervalued and present a good buying opportunity. Q2 earnings report indicates Novartis beating estimates and raising its forecast further. Potential threats include the failure of
Cosentyx achieving the primary goal in an Arteritis Phase III Study. However, Novartis still holds a strong branded drug portfolio, suggesting steady, long-term growth.
Novartis Stocks News Analytics from Tue, 29 Oct 2024 07:00:00 GMT to Fri, 08 Aug 2025 18:29:07 GMT -
Rating 8
- Innovation 7
- Information 7
- Rumor -2
